These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11762075)

  • 1. [Molecular strategy for parasitism and vaccine development of falciparum malaria].
    Horii T
    Tanpakushitsu Kakusan Koso; 2001 Dec; 46(15):2154-62. PubMed ID: 11762075
    [No Abstract]   [Full Text] [Related]  

  • 2. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
    Ballou WR; Kester KE; Heppner DG
    Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of vaccines against falciparum malaria.
    Ramalingam S; Mathai E
    Natl Med J India; 1996; 9(3):120-4. PubMed ID: 8664822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview: immunology of malaria and progress in malaria vaccine development.
    Tharavanij S
    Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
    [No Abstract]   [Full Text] [Related]  

  • 6. [The immunological aspects of tropical malaria related to the development of an antimalarial vaccine].
    Chirkov VP; Popov AF
    Med Parazitol (Mosk); 2000; (2):56-8. PubMed ID: 10900926
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.
    Cowman AF; Baldi DL; Duraisingh M; Healer J; Mills KE; O'Donnell RA; Thompson J; Triglia T; Wickham ME; Crabb BS
    Philos Trans R Soc Lond B Biol Sci; 2002 Jan; 357(1417):25-33. PubMed ID: 11839179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hope but challenge for developing a vaccine that might control malaria.
    Good MF
    Eur J Immunol; 2009 Apr; 39(4):939-43. PubMed ID: 19350585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
    Moorthy SA; Yasawardena SG; Ramasamy R
    Vaccine; 2009 Aug; 27(36):4947-52. PubMed ID: 19545652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A synthetic vaccine against Plasmodium falciparum].
    Fleischer B
    Dtsch Med Wochenschr; 1993 Sep; 118(38):1385-6. PubMed ID: 8404485
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccinating with the genome: a Sisyphean task?
    Coppel RL
    Trends Parasitol; 2009 May; 25(5):205-12. PubMed ID: 19359219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface antigens of Plasmodium falciparum gametocytes--a new class of transmission-blocking vaccine targets?
    Sutherland CJ
    Mol Biochem Parasitol; 2009 Aug; 166(2):93-8. PubMed ID: 19450726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malaria. A complex new vaccine shows promise.
    Vogel G
    Science; 2004 Oct; 306(5696):587-9. PubMed ID: 15498976
    [No Abstract]   [Full Text] [Related]  

  • 14. Malaria vaccines: the stage we are at.
    Todryk SM; Hill AV
    Nat Rev Microbiol; 2007 Jul; 5(7):487-9. PubMed ID: 17571459
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunological challenge to developing a vaccine to the blood stages of malaria parasites.
    Good MF; Stanisic D; Xu H; Elliott S; Wykes M
    Immunol Rev; 2004 Oct; 201():254-67. PubMed ID: 15361246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
    Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
    Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
    Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.